SHIH-HUNG YANGKuo Y.-H.YU-WEN TIENCHIUN HSUCHIH-HUNG HSUSUNG-HSIN KUOANN-LII CHENG2020-02-202020-02-2020110030-2414https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054797356&doi=10.1159%2f000330817&partnerID=40&md5=060fd74ffb16923b76e4a424e02d8ca4https://scholars.lib.ntu.edu.tw/handle/123456789/461868Background: Advanced pancreatic cancer, even when treated, is highly lethal. The best choice of gemcitabine-based therapy and the prognostic factors affecting the success of treatment remain uncertain. Methods: We identified 159 of 1,475 patients with pancreatic cancer diagnosed in our institution and receiving gemcitabine-based chemotherapy between January 1995 and June 2007. Univariate and multivariate analyses were used to evaluate the prognostic significance of various clinical parameters for overall survival (OS). Results: The median survival after gemcitabine-based therapy was 5.4 months; 89.9% (n = 143) had ductal adenocarcinoma, 55.3% (n = 88) with stage IV. Gemcitabine alone was given to 60 (38%) patients, and gemcitabine with high-dose infusional fluorouracil (5-FU) with (n = 25) or without (n = 39) oxaliplatin was given to 64 (40%) patients. All regimens correlated with OS (p = 0.042) but not with the response rate (RR; p = 0.3). The overall RR was 11.1%, and all responders had a good performance status (PS). The RRs to gemcitabine with infusional 5-FU, and gemcitabine with oxaliplatin and infusional 5-FU were 5.3 and 20.8%, respectively. In a multivariate analysis, old age, advanced stage, poor PS and no enrollment in clinical trials were associated with inferior survival. Conclusions: The outcome for patients who did not participate in clinical trials, regardless of gemcitabine-based treatment, is still bleak. Copyright ? 2011 S. Karger AG, Basel.[SDGs]SDG3bevacizumab; capecitabine; carboplatin; cisplatin; erlotinib; fluorouracil; folinic acid; gemcitabine; gimeracil plus oteracil potassium plus tegafur; oxaliplatin; pemetrexed; tegafur; adult; aged; article; cancer combination chemotherapy; cancer patient; cancer staging; cancer survival; clinical trial (topic); drug megadose; female; human; low drug dose; major clinical study; male; overall survival; pancreas cancer; priority journal; prognosis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Republic of Korea; Treatment Outcomejournal article10.1159/000330817220249662-s2.0-80054797356